Therapie des rezidivs beim hodentumor

Translated title of the contribution: Therapy for recurrent testicular cancer

M. Kuczyk*, M. Horstmann, A. Merseburger, J. Beyer

*Corresponding author for this work


In the case of an insufficient response to primary treatment or a tumor relapse, regardless of an initially complete remission, conventional as well as high dose chemotherapy regimens are available as salvage therapy for metastatic germ cell tumors. A multimodal approach should include the radiation of simultaneously occurring brain metastases as well as the surgical resection of residual tumour masses still detectable after completion of chemotherapy. Nowadays, an attempt is made to adjust the salvage modality selected to the individual situation according to a risk stratification of patients. However, a recurrence-free survival of 50% is worse when compared with that observed after primary chemotherapy. Salvage therapy should be reserved for specialized centres due to the increased complexity of a salvage approach and a significantly increased therapy-induced morbidity.

Translated title of the contributionTherapy for recurrent testicular cancer
Original languageGerman
JournalUrologe - Ausgabe A
Issue number4
Pages (from-to)352-357
Number of pages6
Publication statusPublished - 04.2005

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Therapy for recurrent testicular cancer'. Together they form a unique fingerprint.

Cite this